a statement from the CEO such as "we won't be entertaining any acquisitions until IMET has sufficiently developed marketability" would go a long way in curtaining MLV\s shorting activity. He hung that noose over shareholder' heads purely for their trading benefit.
although that talking head panel discussion was informative it did allow a 6% SP drop to follow, indicating no one is seriously buying into this story, yet. Phase ll IMET Infusions have yet to start and any preliminary data review will be at least 3 months in coming following first infusions. The phase ll trial comparative initial endpoint with JAK...namely spleen size reduction will be an easy quick endpoint to reach. The second endpoint; CR's and PR's will take longer and validate IMET for a possible BTS from the FDA. Timelines appear way out there on the govt. trial site March 2017 for primary results and 2018 for trial completion. If however IMET proves it's efficacy hands down earlier in the trial, the FDA has been known to stop the trials early and grant BAT status. IMET already has exhaustive trial data so a hop, skip & jump to BAT may be in order if Janssen can replicate the MAYO study results early. The FDA owes GERN a favour in light of the questionable senseless trial hold they placed on IMET last year.
"Estimated Enrollment: 200
Study Start Date: June 2015
Estimated Study Completion Date: March 2018
Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)"
so U_ Believe_Iwish, what would you do in such a circle of scientology I wonder? Ask me no more questions? Tell me no more lies? pass the koolaid and get drunk. Have you ever heard the phrase healthy dose of skepticism? Actually if all the pumping jerks like yourself joined your circle jerk and left this board I would support your efforts.
the MDS phase trial will start this year but I believe milestone further milestone payments on this wn't happen till data is evaluated next year sometime. We could get another cattle list as in another ASH leak, fast track designation under BT or priority review or even something from across the pond in Belgium. It would be an udder catastrophe fur shorts
the current SMA are setting up for a bullish run. 2 days out from the 20SMA crossing above the 200SMA. A few weeks away from the golden cross, opposite the death cross we saw in Sept when the SP dropped from $3.65 down to $2.60. We should regain our loss and then some. Charts don't lie, people do. The trend is your friend.
Imetelsat acts as a competitive enzyme inhibitor that binds and blocks the active site of the enzyme (a "telomerase template antagonist"), a mechanism of action which differs from that for the antisense oligonucleotide-mediated inhibition of telomerase activity through telomerase mRNA binding. Inhibition of telomerase activity in tumor cells by imetelstat results in telomere shortening, which leads to cell cycle arrest or apoptosis. I other words same results in arresting and killing cancer cells as injecting micro RNA in aggressive tumors. As the article stated this new Mayo research discovery is still a long ways off to clinical applications and that this new discovery will not be the silver bullet to cure cancer but goes a ways into a better understanding of the disease. and potential treatments. IMET is in phase ll trials and has shown unprecedented efficacy in treating MF and possibly other bone marrow cancers. IMET will rise like a phoenix, facial hair and all.
just getting tired/bored of all the mindless pumping & or bashing with deliberate misleading intent by characters devoid of such. Hairy Potter entitles his thread "This is why GERN is falling" and then proceeds to pick through pointers in a recent publication omitting salient comments by the researchers such as, “I think in reality it is unlikely that you could reverse tumours by reversing just one mechanism, but it’s a very interesting finding,” concluded Dr. Chris Bakal from the Institute for Cancer Research in London."
IMET is in an advanced clinical phase ll/lll study possibly being granted BTS early as trial results substantiate earlier findings using a totally different mechanism whilst the article sited new science on another that is still in a lab research phase. Big difference.
Lichtinger said "he was confident the data would be positive but was not expecting miracles", unlike IMET which is "transformational"
....wish I had kept those AST shares. Hope Maine gets caught by Larry the lobster whilst fishin in Maine
as Ryan Wiseman predicted "we will never see $4.30 again"
Why is Chippy so itchy to buy another company/s when we have yet to make any profits from IMET. He sold off all of the previous pipeline and slashed the staff in half only to pay a premium price on acquiring another early staged pharma. This guy has been reckless with my investment. Don't shareholders have to vote on any such acquisition? Here come another string of class actions. Am I the only one that sees this as a drag on SP? MLV shorting to Kingdom come all over again. AST share price $4.68....a cent above our 52 week hih seems like an impossible reach for GERN now.
Offering bonuses to a CEO to improve shareholder returns doesn’t improve the company’s performance, according to a new study.
Maybe Chippy could just cover travelling expenses driving his porch to & fro and consider working for GERN strictly as a charity. After all that is what LT shareholders have done, unwittingly or not.
I heard George Soros was buying it from under the Baker Bros. Once the two brothers realize that it's a 3rd buyer not each other SP will SOAROS!
Today looking at the 3 month chart comparison of GERN it broke above the IBB chart for the first time. Looks like the market may be finally coming around to placing a higher premium on our SP. Now to keep this momentum going till ASH. Joko keep your evaluations within reason please.
4 more recruiting 2 Taiwanese; Chiay & 2 German sites; Aachen & Leipzig.....what a leap!
and bet your bottom dollar SP that Janssen will make an offer before then.
we had no idea the emerge would be a phase 3 until it was updated in Nov. which leads me to believe your hunch is right. Waldo is right in front of us within a hand reach yet we can;t seem to find him.
well that won't happen till he books Janssen $35m upfront payment. So another full month of SP decline. I'm surprised short numbers aren't at their full 30mil high.
Ever think management may pull a dilution bfr. in case J&J decided to bail. Zero infusions 4 months into the trial. This doesn't pass the sniff test. Worst that could happen is SP tanks another $2 and we get another round of class action suits
what about fiduciary duty to shareholders in keeping them abreast of ANY developments? That is precisely what the judge said in giving guidance to the plaintiff on the last class action GERN faced. Chippy wasn't found liable to have said too much about IMET but rather too little to shareholders.